Today June 2n/a2022, Nanologica AB (publ) held its annual general meeting for the financial year 2021, where the following resolutions were adopted.

Adoption of the income statement and balance sheet for the 2021 financial year and disposal of the result
The annual general meeting adopted the income statement and the balance sheet of the company and the group in accordance with the accounting documents presented and decided, in accordance with the proposal of the board, that the cumulative loss of -46,224,712 SEK be carried forward. The decision therefore means that no dividend will be paid for the 2021 financial year.

Discharge of responibility
The annual general meeting discharged the members of the board of directors and the CEO from all liability for the 2021 financial year.

Board of directors and attendance fees
In accordance with the nomination committee’s proposal, ordinary board members Gisela Sitbon, Mattias Bengtsson, Eva Byröd, Thomas Eldered, Tomas Kramar, Anders Rabbe and Lena Torlegård were re-elected as board members, all for a term of up to at the end of the next annual general meeting. Gisela Sitbon was re-elected chair of the board.

In addition, the annual general meeting decided on the fees of the board of directors and the fees for the work of the committees in accordance with the proposal of the nomination committee as follows: 290,000 SEK to the chairman of the board, 170,000 SEK to each of the other members of the board, SEK 50,000 to the chairman of the audit committee, SEK 30,000 to each of the other members of the audit committee, 25,000 SEK to the chairman of the remuneration committee and 15,000 SEK to each of the other members of the compensation committee. The resolution means that the level of remuneration of the Chairman of the Board of Directors and of the members of the Board of Directors has been adapted compared to the previous mandate.

The auditor and the fees of the auditor
The meeting resolved, in accordance with the nomination committee’s proposal, to re-elect the registered accounting firm BDO AB as auditor of the company for the period until the end of the next annual general meeting, with the chartered accountant Niclas Nordström as auditor in charge. Auditor fees must be paid in accordance with the approved invoice.

Appointments Committee and instruction of the Appointments Committee
The Annual General Meeting resolved to establish a Nominating Committee and Nominating Committee Instructions in accordance with the Nominating Committee’s proposal.

Guidelines for Executive Compensation
The Annual General Meeting decided, in accordance with the Board’s proposal, to adopt guidelines for the remuneration of senior executives.

Remuneration report for the financial year 2021
The annual general meeting has decided to approve the remuneration report for the financial year 2021.

Authorization to be given to the Board of Directors to decide on the issue of new shares
In accordance with the board’s proposal, the annual general meeting has decided to authorize the board of directors to, on one or more occasions during the period until the next annual general meeting, decide on the issue of shares , convertible bonds and/or warrants with or without waiver of shareholders’ preferential rights and with or without consideration in kind and/or compensation or otherwise with conditions. the Board of Directors may not, in the event of issues carried out with derogation from the preferential right of shareholders, take a decision having the effect that the amount of the increase in the share capital corresponds to more than twenty (20) percent of the the entire share capital of the company – at the time of the first use of the authorization – after the completion of the issue.

Proposal on incentive program for CEO, management and other employees withdrawn
On May 31, 2022, it was announced that the board had decided to withdraw the proposal for a new incentive program for the CEO, management and other employees as presented in the notice of meeting. The reason for the withdrawal is that the board wishes to await the outcome of the option programs which expire on July 1, 2022. Depending on the outcome, a new option program may be offered later this year.

For more information, please contact:

Johanna Johansson, IR Director, Communications and Marketing
Telephone: +46 72 211 21 90 or email: [email protected]

About Nanologica AB (publ)
Nanologica manufactures, develops and sells nanoporous silica particles for life science applications. Nanologica is the world leader in controlling the shape, size, porosity and surface properties of silica particles, creating opportunities to develop unique products. Through the two business areas, Drug Development and Chromatography, the company strives to increase the accessibility of innovative healthcare treatments and medicines for the benefit of patients worldwide. In the area of ​​drug development, Nanologica provides a unique drug delivery platform for the local delivery of drugs to the lungs with the goal of providing new treatment options for patients with lung diseases. In the field of chromatography, the company aims to make insulin accessible to more patients in need, by reducing the cost of manufacture. Nanologica is headquartered in Södertälje, and the company’s stock (NICA) has been listed on Nasdaq Stockholm since March 29, 2022. For more information, please visit www.nanologica.com.

This is a translation of the original Swedish press release. In case of discrepancies, the original press release in Swedish prevails.

2022-06-02 Nanologica AB Annual General Meeting Bulletin (publ)